Due to the lack of effective early diagnostic measures and treatment methods, bladder cancer has become a malignant tumor that seriously threatens people's lives and health. Here, we reported that LINC00162, a super-enhancer long noncoding RNA, was highly expressed in bladder cancer cells and tissues. And LINC00162 was negatively correlated with neighboring PTTG1IP expression. Knocking down LINC00162 expression can inhibit the proliferative activity of bladder cancer cells and the growth of transplanted tumors in vivo, while knocking down the expression of PTTG1IP could restore the proliferative activity of bladder cancer cells. In addition, both LINC00162 and PTTG1IP were found to be able to bind to THRAP3, a transcription-related protein. And THRAP3 can regulate PTTG1IP expression. Finally, we demonstrated a mechanism that LINC00162 could regulate PTTG1IP expression through binding THRAP3. This study provided a potential target molecule for clinical treatment of bladder cancer.

由于缺乏有效的早期诊断措施和治疗方法，膀胱癌已成为严重威胁人们生命和健康的恶性肿瘤。在这里，我们报道了LINC00162，一种超增强型长非编码RNA，在膀胱癌细胞和组织中高度表达。LINC00162与邻近的PTTG1IP表达负相关。敲低LINC00162的表达可抑制膀胱癌细胞的增殖活性和体内移植肿瘤的生长，同时降低PTTG1IP的表达可以恢复膀胱癌细胞的增殖活性。此外，发现LINC00162和PTTG1IP都能够与THRAP3（一种转录相关蛋白）结合。THRAP3可以调节PTTG1IP的表达。最后，我们证明了LINC00162可以通过结合THRAP3来调节PTTG1IP表达的机制。该研究为膀胱癌的临床治疗提供了潜在的靶分子。